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1. Introduction  
Fatal sepsis during chemotherapy-induced neutropenia is the most severe complication of 
which physicians must be keenly aware. Common bacterial pathogens in neutropenic 
patients usually include gram-positive cocci such as coagulase-negative staphylococci, 
Staphylococcus aureus, Enterococcus species, and gram-negative rods such as Escherichia coli, 
Klebsiella species, Enterobacter species, and Pseudomonas aeruginosa (Wisplinghoff, et al 
2003). Thus, clinical practice guidelines for the use of antibiotics are likely to be aimed at 
targeting these pathogens including antibiotic-resistant strains (Freifeld, et al 2011). In the 
absence of effector cells for these pathogens, the rapid progression of invasive bacterial 
infections may occur; therefore, antibiotics are a life-saving measure during severe 
neutropenia. 
Bacillus cereus (B. cereus) is an aerobic gram-positive, spore-forming, and rod-shaped 
bacterium that is widely distributed in the environment. Although B. cereus is a common 
cause of food-poisoning, abdominal distress such as vomiting and diarrhea is usually mild 
and self-limiting unless the host is immunocompromised. Some patients that undergo 
prolonged hospitalization have Bacillus species as a part of the normal flora in their intestine 
(Drobniewski 1993). Therefore, identification of this microorganism in clinical cultures has 
usually been considered to be due to contamination. For example, 78 patients were found to 
have cultures positive for B. cereus in a single center in the United States; however, only 6% 
of them resulted in clinically significant infections (Weber, et al 1989). On the other hand, B. 
cereus is a growing concern as a cause of life-threatening infections in patients with 
hematologic malignancies, including septic shock, brain abscess, meningitis, colitis, 
respiratory infections, endocarditis, and infection-related coagulopathy and hemolysis. The 
risk factors for patients with unfavorable outcomes, however, have not been totally 
elucidated. In addition, B. cereus sepsis generally does not respond to any antibiotics in spite 
of their in vitro efficacy (Drobniewski 1993). Akiyama et al. reviewed 16 case reports of B. 
cereus sepsis in patients with leukemia, and consequently reported only 3 survivors 
(Akiyama, et al 1997). Therefore, physicians should identify specific risk factors of B. cereus 
sepsis during chemotherapy for leukemia patients and establish a proper strategy to 
overcome this life-threatening sepsis. 
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2. B. cereus sepsis in patients with hematologic malignancies 
In recent years, we encountered several cases of B. cereus sepsis including 4 fatal cases with 
acute leukemia in our hospital. These episodes prompted us to review all cases of B. cereus 
sepsis especially in hematologic malignancies. In the present study, we collected the data 
and the clinical features of these patients with B. cereus sepsis in a retrospective fashion, and 
identified risk factors for a fatal prognosis in these patients (Inoue, et al 2010). Based on these 
data, we also put forward a proposal for the rapid diagnosis of B. cereus sepsis and earlier 
therapeutic intervention for this infection. 
2.1 Patients and methods 
We reviewed the microbiology records of all patients who produced a positive blood culture 
for B. cereus from September 2002 to November 2009 in our hospital. We routinely took at 
least two sets of blood culture samples from all patients with hematologic malignancies who 
developed a high-grade fever of over 38℃. Each set consisted of two blood culture vials for 
both aerobic and anaerobic cultures. Identification of B. cereus was made on the basis of 
Gram-staining, colony morphology, and analysis with NGKG agar (Nissui, Tokyo, Japan). 
Antimicrobial disk susceptibility tests were performed using Sensi-Disc (Beckton 
Dickinson). 
We defined a case as sepsis when more than two blood culture sets were positive for B. 
cereus or only a single set was positive in the absence of other microorganisms in patients 
who had definite infectious lesions, such as brain or liver abscesses. Instead, febrile cases 
that did not satisfy the above criteria were defined as an unknown pathogen or 
contaminated culture. 
With regard to sepsis patients, we also reviewed their charts to obtain clinical information, 
including the underlying disease, insertion of a central venous (CV) catheter, nutrition 
route, neutrophil count, and prior chemotherapy or steroid treatment. Oral nutrition was 
defined only when patients were eating a regular diet without high-calorie parenteral 
nutrition support. We also documented clinical signs at febrile events, such as 
gastrointestinal (GI) and central nervous system (CNS) symptoms, antibiotic use, and the 
drug sensitivity of B. cereus. Then, we assessed the risk factors for a fatal prognosis; i.e., 
whether the underlying disease was acute leukemia, whether a CV catheter was inserted, 
whether the patient was receiving oral or parenteral nutrition, whether their neutrophil 
count was 0/mm3 or above 0/mm3, and whether characteristic clinical signs were present at 
the time of febrile events. We also reviewed the charts of patients without hematologic 
malignancies who had cultures positive for B. cereus in the same period. Furthermore, we 
assessed the above data in conjunction with those from previously reported patients with B. 
cereus sepsis, who had hematologic malignancies.  
Statistical tests included χ2 and Fisher’s exact tests. All calculations were made using the 
program JMP 8.0 (SAS Institute, Cary, NC, US). All P-values of <0.05 were considered 
significant. 
2.2 Results 
2.2.1 Characteristics of B. cereus sepsis patients 
A total of 68 febrile patients that produced positive blood cultures for B. cereus were 
identified from September 2002 to November 2009 in our institute. Twenty-three of these 
patients had hematologic malignancies, including 4 patients who died of fatal sepsis. 
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Although 11 of the 23 patients showed signs of infection such as a high-grade fever, we 
classified them with an unknown pathogen or contaminated culture, since other causes of 
fever could not be totally excluded. With respect to underlying diseases, 2 of 5 cases of non-
Hodgkin lymphoma (NHL), 3 of 5 cases of acute lymphoblastic leukemia (ALL), 5 of 6 cases 
of acute myeloid leukemia (AML), 1 of 4 cases of myelodysplastic syndrome (MDS), and 1 of 
3 cases of multiple myeloma (MM) were diagnosed with B. cereus sepsis. Thus, we 
determined as many as 12 (patients 1 to 12) of 23 patients with hematologic malignancies as 
having B. cereus sepsis; whereas, only 10 of 45 patients without hematologic malignancies 
were similarly diagnosed on the basis of the same criteria (P=0.012). All of these 10 patients 
recovered from B. cereus sepsis after treatment with appropriate antimicrobials including 
carbapenems, vancomycin, or fluoroquinolones. None of the 10 patients received 
chemotherapy. Their underlying diseases were as follows: chronic obstructive pulmonary 
disease, congestive heart failure, bronchial asthma, acute hepatitis, malnutrition, 
subarachnoid hemorrhage, ovarian cancer, gastric cancer, and cerebral infarction in 2 
patients. 
As shown in Table 1, we analyzed the profiles of the 12 patients with hematologic 
malignancies: 6 men and 6 women with a median age of 53.5 ranging from 20 to 85 years; 8 
patients with acute leukemia, 5 who were treated with a CV catheter and 12 who received 
oral nutrition; 5 patients with a neutrophil count of 0/mm3; all patients, except for patients 
5, 10, and 12, had undergone prior steroid treatment within 2 weeks; and 8 patients 
exhibited GI symptoms including nausea, vomiting, diarrhea, and abdominal pain, and 6 
patients displayed CNS symptoms ranging from disorientation to deep coma at the time of 
febrile episodes. Although CV catheters were removed in patients 2, 4, 6, and 12 as a part of 
the management for their febrile status, none of these catheters were found to be positive for 
B. cereus. In one patient (patient 6), postmortem cultures from CSF samples were performed, 
with positive results for B. cereus. Among 5 patients with CNS symptoms, lumbar puncture 
was only performed in patient 8, without B. cereus isolation. Lumbar puncture was not 
conducted for the remaining 4 patients because of their unstable conditions. No patient 
demonstrated other organisms as co-isolates in their initial blood cultures. 
Patients 1 and 2, who had ALL, and patients 6 and 12, who had AML, developed 
consciousness disturbance, which resulted in a deep coma and brain stem dysfunction 3 
days, 6 hours, 18 hours, and 8 hours after their febrile episode and they died 12 days, 7 days, 
20 hours, and 15 hours after their febrile event, respectively, despite intensive antimicrobial 
therapy and supportive care (Table 1). All 4 patients had received intensive chemotherapy 
for acute leukemia, and febrile events occurred on day 13 after re-induction chemotherapy 
in patient 1; on day 18 after induction therapy in patient 2; on day 14 after consolidation in 
patient 6; and day 13 after induction therapy in patient 12. On the other hand, patient 7, who 
had received high-dose etoposide for the collection of peripheral blood stem cells, similarly 
developed a deep coma but recovered without sequela 28 hours after the onset of 
consciousness disturbance. Patients 8, 9, 10, and 11 also received intensive chemotherapy 
prior to B. cereus sepsis, as shown in Table 1. Patient 4 received methylprednisolone 
treatment (20 mg/day) for chronic graft-versus-host disease when the sepsis developed. The 
characteristics of the remaining patients are also shown in Table 1. In addition to patients 1, 
2, 6, and 12, patient 8 died of underlying refractory AML 6 months after the onset of B. cereus 
brain abscesses despite successful treatment of the abscesses with long-term vancomycin 
administration, and patient 4 died of multiple organ failure caused by another bacterial 
infection 11 months later. No sequela or death occurred in the remaining patients, including 
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patient 9, in whom the long-term administration of vancomycin was required for liver 
abscesses. Patients 9 and 10 successfully received allogeneic bone marrow transplantation 
(BMT) after recovering from severe B. cereus sepsis. 
2.2.2 Results of autopsies 
Of the 4 fatal cases, we performed autopsy in 3 patients. Autopsy of patient 2 demonstrated 
the presence of a small number of B. cereus in the subarachnoid space and venous 
thrombosis in the Vein of Galen and the superior sagittal sinus. In contrast, coagulation 
necrosis with bacterial infiltration in the liver and necrotizing leptomeningitis with 
subarachnoid hemorrhage (SAH) were observed in patient 6, and coagulation necrosis 
accompanied by B. cereus infiltration in the colon could be seen in patient 12. Histologic 
analyses of organs obtained in the autopsies of patients 2 and 6 are shown in Figure 1. Large 
venous thromboses in the vein of Gallen and superior sagittal sinus can be seen in patient 2 
(A and B, H.E. staining, ×40). On the other hand, in patient 6, numerous gram-positive rods 
are present in the subarachnoid space (D, Gram staining, ×400) and outside of the 
subarachnoid membrane (E, H.E. staining, ×100, in the circle), which may have caused the 
coagulation necrosis of the vessels in the subarachnoid membrane (arrows). The coagulation 
necrosis is also seen without the infiltration of inflammatory cells in the surface area of the 
cerebrum (arrowheads), which is distant from the B. cereus clusters. Extensive coagulation 
necrosis with bacterial infiltration stands out without an inflammatory response in the liver 
of patient 6 (C, H.E. staining, ×100). A number of gram-positive rods can be seen clustering 
in the circle. In patient 12, coagulation necrosis with bacterial infiltration could be similarly 
seen in the liver in addition to B. cereus infiltration in the colon, although we could not 
obtain pathological analysis in CNS. 
2.2.3 Risk factors for a fatal prognosis, which were identified in patients in our 
institution 
As shown in Table 1, all 4 fatal cases shared common factors, that is, acute leukemia, 
insertion of a CV catheter, an extremely low neutrophil count, and CNS symptoms at febrile 
episodes. We then statistically analyzed clinical parameters of 12 patients listed in Table 1, 
and identified the following risk factors for death due to B. cereus sepsis: CV catheter 
insertion (P=0.010), a neutrophil count of 0/mm3 (P=0.010), and CNS symptoms at the time 
of febrile events (P=0.010). While acute leukemia (P=0.141), GI symptoms (P=0.594), and 
prior steroid treatment within 2 weeks (P=0.764) did not show a close relationship with a 
fatal course of B. cereus sepsis. 
2.2.4 Antibiotic susceptibility 
The antibiotics employed in the present study included meropenem or doripenem for 8 
patients (patients 2, 6-12) and vancomycin for 7 patients (patients 2, 6, 8-12). All of the 
isolated B. cereus strains were susceptible to imipenem, vancomycin, levofloxacin, and 
gentamicin; whereas, no isolated B. cereus strains, except for that from patient 5, were 
sensitive to penicillins or cephalosporins in vitro. 
2.2.5 Risk factors for a fatal prognosis in previously reported patients and ours 
To our knowledge, 46 B. cereus sepsis patients with hematologic malignancies have been 
previously reported (Akiyama, et al 1997, Arnaout, et al 1999, Christenson, et al 1999, Colpin, 
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Fig. 1. Histologic analyses of organ specimens obtained in the autopsies of patients 2 and 6 
et al 1981, Cone, et al 2005, Coonrod, et al 1971, Dohmae, et al 2008, Feldman and Pearson 
1974, Frankard, et al 2004, Funada, et al 1988, Garcia, et al 1984, Gaur, et al 2001, Ginsburg, et 
al 2003, Ihde and Armstrong 1973, Jenson, et al 1989, Katsuya, et al 2009, Kawatani, et al 2009, 
Kiyomizu, et al 2008, Kobayashi, et al 2005, Kuwabara, et al 2006, Le Scanff, et al 2006, Leff, et 
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al 1977, Marley, et al 1995, Motoi, et al 1997, Musa, et al 1999, Nishikawa, et al 2009, 
Ozkocaman, et al 2006, Sakai, et al 2001, Strittmatter, et al 1995, Tomiyama, et al 1989, Trager 
and Panwalker 1979, Yoshida, et al 1993). On analyses of the clinical parameters of these 
patients, as in shown in Table 2, patients with acute leukemia, a neutrophil count of 0/mm3 
or below the lower limit of each institute, or CNS symptoms at febrile episodes were 
identified as risk factors closely correlated with a fatal prognosis (P=0.044, 0.004, and 0.002, 
respectively). Patients younger than 15 years old had a tendency to show a more favorable 
prognosis in comparison with older patients. (P=0.063). Male, GI symptom, corticosteroid 
administration, CV catheter insertion, and antimicrobial therapy except for that with 
vancomycin did not have a significant impact on the prognosis. 
2.3 Discussion and proposal 
2.3.1 How do we efficiently select high-risk patients? 
Our report contains 12 adult B. cereus sepsis cases of hematologic malignancy, which is, to 
our knowledge, the largest cohort of B. cereus sepsis in adult patients from a single center. 
Because of the serious outcomes of these patients with hematologic malignancies, the 
detection of B. cereus from blood culture samples at febrile events from these patients should 
not be regarded as contamination. In our cohort, patients with a neutrophil count of 0/mm3, 
with CNS symptoms, or who had undergone CV catheter insertion definitely had a poor 
prognosis. However, we had difficulties in identifying further precise prognostic factors 
because of the small number of B. cereus infection cases in our institution. Therefore, we 
assessed the data in conjunction with those from our 12 patients and from 46 previously 
reported patients, giving a total of 42 patients with acute leukemia, although reporting bias 
may have existed because severe cases with peculiar clinical features tend to be selectively 
reported and some reports did not refer all factors which we consider to be important. 
Consequently, patients who had acute leukemia, a neutrophil count of 0/mm3 or a count 
below the lower limit of each institute, or CNS symptoms at febrile episodes were identified 
as being associated with a fatal prognosis. Interestingly, the relatively more favorable 
prognosis in younger patients implies the importance of appropriate evaluation in adult 
patients (Table 2). 
Regarding the neutrophil count, patients 7, 8, 10, and 11 fully recovered from B. cereus sepsis 
complicated with coma, in clear contrast to patients 1, 2, 6, and 12 who had a neutrophil 
count of 0/mm3 (Table 1), suggesting that both immediate therapeutic intervention and even 
a small number of neutrophils can effectively work against B. cereus sepsis. The poor 
outcomes in acute leukemia patients may have been an indirect consequence because of the 
greater immunosuppression following intensive chemotherapy, rather than due to the 
underlying disease. Regarding the relationship between B. cereus sepsis and the treatment 
process of acute leukemia in the combined clinical parameters, 35 patients developed sepsis 
during remission induction or reinduction therapy, 9 consolidation therapy, 4 post-
transplantation, and 1 maintenance therapy in a total of 49 acute leukemia patients whose 
clinical data were available (Akiyama, et al 1997, Arnaout, et al 1999, Christenson, et al 1999, 
Colpin, et al 1981, Cone, et al 2005, Coonrod, et al 1971, Dohmae, et al 2008, Feldman and 
Pearson 1974, Frankard, et al 2004, Funada, et al 1988, Garcia, et al 1984, Gaur, et al 2001, 
Ginsburg, et al 2003, Ihde and Armstrong 1973, Jenson, et al 1989, Katsuya, et al 2009, 
Kawatani, et al 2009, Kiyomizu, et al 2008, Kobayashi, et al 2005, Kuwabara, et al 2006, Le 
Scanff, et al 2006, Leff, et al 1977, Marley, et al 1995, Motoi, et al 1997, Musa, et al 1999, 
Nishikawa, et al 2009, Ozkocaman, et al 2006, Sakai, et al 2001, Strittmatter, et al 1995, 
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These data include both previous reports and our 12 sepsis patients. P-values were calculated using χ2 
and Fisher’s exact tests. Odds ratios predict the possibility of death from Bacillus cereus sepsis. GI, 
gastrointestinal. CNS, central nervous system. CV, central vein. VCM, vancomycin. 
Table 2. Univariate analysis of prognostic factors of B. cereus sepsis 
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Tomiyama, et al 1989, Trager and Panwalker 1979, Yoshida, et al 1993). Therefore, patients 
under induction or reinduction therapy may be more likely to be susceptible to B. cereus 
sepsis. Also, previous studies have shown that variations in toxins and enzymes, which 
were produced by B. cereus, such as cereolysin, enterotoxin, emetic toxin, phospholipase C, 
and sphingomyelinase, between isolates of B. cereus were correlated with the reversibility of 
clinical courses (Turnbull, et al 1979, Turnbull and Kramer 1983). With respect to clinical 
symptoms related to B. cereus sepsis, patients with CNS disturbance mostly had a fatal 
outcome (P=0.005, in adult patients) (Table 2). Gaur et al. reported that patients with 
possible CNS involvement had a tendency to exhibit severe neutropenia at the onset of 
sepsis and to have an unfavorable outcome, although their study was conducted in a 
children’s hospital (Gaur, et al 2001). Given that most of the patients with a fatal prognosis 
had GI symptoms at the time of febrile episodes (Table 2), clinicians must be cautious of the 
early signs of CNS in addition to GI symptoms. Although GI symptoms were not 
significantly correlated with a fatal prognosis, we consider that the symptoms are very 
important in terms of early clues to the diagnosis of B. cereus sepsis. CV catheter insertion 
did not have a significant impact on the prognosis (P=0.149, in adult patients), although the 
result was opposite to that found in our cohort. 
2.3.2 We have a very limited time to avoid CNS damage in the face of B. cereus sepsis 
With respect to the results of autopsy, the findings observed in patient 2 have not been 
reported elsewhere, although coagulation necrosis with B. cereus infiltration of the liver and 
the GI tract may not be rare in B. cereus sepsis, as demonstrated in patients 6 and 12, 
respectively. In any case, the patients’ condition rapidly deteriorated in spite of intensive 
antibiotic coverage, including carbapenems and vancomycin, which were effective against 
B. cereus in vitro, although these agents (especially meropenem and vancomycin) are still 
recommended because of the inherent ability of B. cereus to produce β lactamases and the 
presence of the blood brain barrier (Hasbun, et al 1999, Zinner 1999). The failure of 
apparently adequate therapy may have been due to inadequate tissue concentrations of 
antibiotics. However, we emphasize that delays in therapeutic intervention must be avoided 
even if the CNS may have already been damaged by B. cereus before the administration of 
adequate antibiotics, as seen in our fatal cases. Patient 7 (Table 1), with a neutrophil count of 
near 0, had consciousness disturbance at the febrile event. We started to treat this patient 
very quickly based on information from Patient 2 and 6 with antibiotics effective for B. 
cereus, with the successful recovery from sepsis including CNS symptoms. This experience 
may be very important in terms of the necessity of very early therapeutic intervention. 
2.3.3 Proposal: Initial management of fever and neutropenia in AML patients in view 
of fatal B. cereus sepsis  
According to the Infectious Diseases Society of America (IDSA) guideline for neutropenic 
patients with cancer, ‘high-risk’ patients are considered to be those with anticipated 
sustaining (>7-day duration) and profound neutropenia (absolute neutrophil count (ANC) 
<100 cells/mm3) and/or significant medical co-morbid conditions, including hypotension, 
pneumonia, new-onset abdominal pain, or neurologic changes (Freifeld, et al 2011). It is 
generally assumed that all AML patients during intensive chemotherapy meet the high-risk 
criteria.  
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In the face of febrile AML patients, physicians should evaluate a complete blood count 
including a differential leukocyte count, although therapeutic intervention must be 
performed without delay in cases when the neutrophil count is expected to be 0/mm3 or 
below the lower limit of each institute. At least 2 sets of blood culture are recommended, 
with a set collected simultaneously from each lumen of an existing CV catheter and from a 
peripheral vein. Without a CV catheter, 2 sets of blood culture should be obtained from 
different peripheral sites. The number of blood cultures has been described as correlated 
with the detectability of circulating pathogens, that is, only a single blood culture may cause 
misevaluation regarding underlying pathogens (Lee, et al 2007).  
In the IDSA guideline, high-risk patients require initial antibiotic therapy that covers 
Pseudomonas aeruginosa and other serious gram-negative pathogens (Freifeld, et al 2011). 
Although the isolation of gram-positive organisms, such as coagulase-negative 
staphylococci, is more common than that of gram-negative pathogens, gram-negative 
bacteremias, especially those caused by Pseudomonas aeruginosa, are generally associated 
with greater mortality (Schimpff 1986). Thus, empirical monotherapy with an anti-
pseudomonal β-lactam agent, such as cefepime, carbapenem (meropenem or imipenem-
cilastatin), or piperacillin-tazobactam, is recommended and vancomycin should be 
considered only for clinically special indications, including suspected catheter-related 
infection, skin or soft tissue infection, pneumonia or hemodynamic instability (Freifeld, et al 
2011). Coagulase-negative staphylococci, the most commonly identified microorganisms in 
septic patients with neutropenia, are clinically weak pathogens that rarely cause rapid 
deterioration; therefore, for many physicians, there is no urgent need to treat such infections 
with vancomycin at the time of a febrile event.  
However, such a strategy as described above does not sufficiently satisfy appropriate 
treatment for fatal B. cereus sepsis, since B. cereus has an inherent ability to produce β 
lactamases (Hasbun, et al 1999, Zinner 1999). If neutropenic patients really suffer from B. 
cereus sepsis, it takes at least a few days to determine bacterial strains and, meanwhile, the 
patients’ condition rapidly deteriorates. Although physicians should avoid the unnecessary 
administration of broad-spectrum antibiotics to prevent widely distributing resistant 
bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant 
enterococcus (VRE), extended-spectrum β lactamase (ESBL)-producing gram-negative 
bacteria, and Klebsiella pneumonia carbapenemase (KPC), therapeutic delays for B. cereus 
sepsis would result in a fatal outcome.  
Therefore, as shown in Figure 2, at the first febrile event, we propose the prompt 
administration of both carbapenems and vancomycin for the following neutropenic AML 
patients with possible B. cereus sepsis, especially for patients with a neutrophil count of 
0/mm3 or below the lower limit of each institute, and CNS symptoms at febrile episodes. 
These 2 antibiotics are also desirable for febrile and neutropenic AML patients with CV 
catheter insertion or GI symptoms (Inoue, et al 2010). We consider that both agents are 
necessary as an initial management because of the presence of fulminant sepsis with B. 
cereus resistant to carbapenem (Kiyomizu, et al 2008). CV catheter removal is recommended 
if clinically possible. In patients with clinically and microbiologically documented infections 
other than B. cereus, appropriate agents should be started instead of carbapenems and 
vancomycin, and the duration of therapy depends on the species of pathogen and their 
infection site.  
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Fig. 2. Initial and urgent management for fever and severe neutropenia in AML patients in 
view of fatal B. cereus sepsis 
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The IDSA guideline recommends fluoroquinolone prophylaxis for high-risk patients with 
expected durations of prolonged and marked neutropenia (ANC≦100/mm3 for >7 days) to 
reduce febrile events, documented infections, and infections involving the blood stream due 
to gram-positive or -negative bacteria (Bucaneve, et al 2005). Although fluoroquinolones, 
such as levofloxacin and ciprofloxacin, are usually efficacious against B. cereus in vitro and 
may prevent the rapid production of a large amount of bacterial toxins, there has been no 
report concerning the prophylactic efficacy of antibiotics against B. cereus sepsis (Bucaneve, 
et al 2005, Freifeld, et al 2011, Gafter-Gvili, et al 2005). The question of whether gut 
decontamination with oral fluoroquinolones can contribute to the reduction of B. cereus-
related mortality remains to be addressed.  
Fungal infections are encountered after the first week of prolonged neutropenia and 
empirical antibiotic therapy in the early phase of neutropenia, so that empirical antifungal 
therapy and investigation for invasive fungal infections should be considered for patients 
with persistent or recurrent fever after 2-4 days of antibiotics, including cases receiving 
prophylactic agents against Candida infections or invasive Aspergillus infection  (Freifeld, et 
al 2011). Also, physicians should recurrently monitor possible fungal infection using the β-
(1-3)-D glucan test, the galactomannan test, and high-resolution CT, leading to pre-emptive 
therapy if necessary. 
2.3.4 What kind of environmental precautions should be taken? 
It is reasonable to assume that B. cereus, which forms spores and is heat-resistant, in the 
environment or food passes through the GI tract or a CV catheter and enters into the 
circulation based on the results and information from our cases and previously reported 
patients (Banerjee, et al 1988, Terranova and Blake 1978). Especially, GI symptoms were 
present prior to the development of B. cereus sepsis in 8 cases, while no organism was 
grown from the tip of a CV catheter in any case (patients 2, 4, and 6) (Table 1). We 
regarded bananas, strawberries, and fried noodles as possibly causative foods in patients 
1, 2, and 6, respectively. In these patients, the impairment of mucosal barriers due to 
intensive chemotherapy may have been an important factor; therefore, clinicians should 
pay strict attention to the foods consumed by such patients and prepared luncheon meats 
should be avoided, although Gardner et al. reported that avoidance of raw fruits and 
vegetables did not prevent major infection that led to death among AML patients in a 
randomized trial where cooked and noncooked food diets were compared (Gardner, et al 
2008). 
In previous reports, the inadequate sterilization of respiratory circuits (Bryce, et al 1993) and 
bacterial contamination of hospital linen (Barrie, et al 1994, Dohmae, et al 2008) were also 
considered to be major sources of nosocomial infection. B. cereus sepsis in patients 2 and 3 
occurred in the same room and the same period (May, 2007). These facts prompted us to 
compare each B. cereus strain cultured from the blood samples of the 2 patients with B. cereus 
detected from hand towels, pajamas, a shared sink, and so on. However, each train proved 
distinct from the other strains detected, suggesting little possibility of nosocomial infection. 
Although B. cereus is widely distributed in the environment, the bacterial burden should be 
minimized because the threshold of the burden might determine the frequency of B. cereus 
sepsis. From this point of view, the regular surveillance of B. cereus strains in the 
environment may also be important. 
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3. Conclusion 
We encountered fatal B. cereus sepsis in patients with acute leukemia, in whom apparently 
appropriate antibiotics were not effective, while we also encountered reversible cases. This 
report has provided risk factors for a fatal prognosis in combination with previous data. It 
may be highly instructive for clinicians treating leukemia patients with several prognostic 
factors identified in this study for B. cereus sepsis with special relevance to patients with 
acute leukemia, and we strongly recommend the immediate initiation of treatment with 
carbapenems and vancomycin in such situations. Similar studies with a larger cohort are 
necessary to establish successful therapeutic interventions. 
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